2024
Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study
Worhunsky P, Mignosa M, Gallezot J, Pittman B, Nabulsi N, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone R, Carson R, Malison R, Potenza M, Angarita G. Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study. Biological Psychiatry 2024 PMID: 39395473, DOI: 10.1016/j.biopsych.2024.09.028.Peer-Reviewed Original ResearchVentral striatumEffects of medicationDorsal caudateDopamine releaseDorsal putamenDopaminergic tonePlacebo-controlled within-subject studyIncreased amphetamine-induced dopamine releaseAmphetamine-induced dopamine releaseAmphetamine-stimulated dopamine releaseSubstantia nigraDysregulated dopamine functionPositron emission tomography studiesTreatment of ADHDEmission tomography studiesWithin-subject studyPost-amphetamineD2/3 receptorsDopamine functionTransdiagnostic relevanceVitamin DPhasic releaseGlobus pallidusStriatumTyrosine hydroxylaseClinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkers
2019
In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET
Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.Peer-Reviewed Original ResearchConceptsHealthy male controlsPositron emission tomographyMultilinear analysis 1Antipsychotic treatmentLower BPFrontal cortexReceptor availabilityAge-matched healthy male controlsDifferent second-generation antipsychoticsSteady-state troughPeak serum levelsSecond-generation antipsychoticsPotential therapeutic targetMale patientsSerum levelsHealthy humansTherapeutic targetSchizophrenia patientsTime-activity curvesMale controlsCognitive impairmentEmission tomographyVentral striatumPatientsSchizophrenia
2018
2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET
Radhakrishnan R, Nabulsi N, Gaiser E, Gallezot J, Henry S, Planeta B, Lin S, Ropchan J, Williams W, Morris E, D’Souza D, Huang Y, Carson R, Matuskey D. 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET. Journal Of Clinical And Translational Science 2018, 2: 3-4. PMCID: PMC6799074, DOI: 10.1017/cts.2018.44.Peer-Reviewed Original ResearchReceptor availabilityEffect of ageHealthy male volunteersSerotonin receptor 6Healthy male subjectsPotential therapeutic targetSignificant age-related declineMultilinear analysis-1 (MA1) methodAge-related changesAge-related declineMale volunteersTherapeutic targetNegative correlationTime-activity curvesReceptor 6PET ligandMale subjectsBrain regionsCortical regionsVentral striatumAgePutamenStriatumCaudateReference region
2016
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology 2016, 41: 3042-3050. PMID: 27374277, PMCID: PMC5101552, DOI: 10.1038/npp.2016.115.Peer-Reviewed Original ResearchConceptsBody mass indexVentral striatumObese individualsD2/3R availabilityOB individualsReward regionsSubstantia nigra/ventral tegmental areaDopamine D2/3 receptor availabilityNormal-weight individualsTreatment of obesityVentral tegmental areaNovel pharmacologic targetsD2/3 receptor availabilitySN/VTAAgonist tracersOverweight cohortMass indexWeight individualsTegmental areaBrain reward regionsAntagonist tracersPharmacologic targetReceptor availabilitySecondary analysisNW individuals
2011
Serotonin 1B receptor imaging in pathological gambling
Potenza MN, Walderhaug E, Henry S, Gallezot JD, Planeta-Wilson B, Ropchan J, Neumeister A. Serotonin 1B receptor imaging in pathological gambling. The World Journal Of Biological Psychiatry 2011, 14: 139-145. PMID: 21936763, PMCID: PMC3595502, DOI: 10.3109/15622975.2011.598559.Peer-Reviewed Original ResearchConceptsSerotonin 1B receptorAnterior cingulate cortexPathological gamblingCingulate cortexVentral striatumBPND valuesMedication-free subjectsSouth Oaks Gambling ScreenPositron emission scanningFunctional neuroimaging studiesSerotonergic mechanismsSerotonergic functionSerotonin receptorsCC subjectsComparison subjectsBrain regionsImaging studiesPG subjectsNeuroimaging studiesPotential roleReceptorsFurther studiesStriatumSubstance addictionCortex